Physician profile
Prashanth Reddy
NPI 1811420763
$1,964.22
in general payments reported to CMS, 2019-2025
24 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $318 · 2023: $464 · 2024: $567 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.34 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $295.05 | 2025 | Rotarexs 6 F X 135 Cm, Lutonix Drug Coated Balloon, Covera |
| Horizon Therapeutics Plc | $287.29 | 2022-2023 | Krystexxa |
| Amgen INC. | $230.72 | 2022-2025 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $214.19 | 2022-2024 | Lupkynis |
| Becton, Dickinson and Company | $190.18 | 2025 | Wavelinq |
| Travere Therapeutics, INC. | $90.12 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $82.86 | 2023-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $68.64 | 2024-2025 | Terlivaz |
| Medtronic, INC. | $53.78 | 2024 | Ellipsys Vascular Access System |
| Vifor Pharma, INC. | $49.31 | 2024 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.35 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $42.87 | 2023-2024 | Farxiga |
| Mozarc Medical US LLC | $39.96 | 2025 | Argyle, Palindrome |
| Angiodynamics, INC. | $34.02 | 2024 | Auryon Laser System 100-120 Vac |
| Calliditas Therapeutics US INC. | $33.14 | 2025 | Tarpeyo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.66 | 2024 | |
| Glaxosmithkline, LLC. | $25.51 | 2022-2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $25.45 | 2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $24.67 | 2024 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Opko Pharmaceuticals, LLC | $20.22 | 2023 | Rayaldee |
| Pfizer INC. | $19.88 | 2023 | |
| Boston Scientific Corporation | $18.06 | 2024 | |
| Philips North America LLC | $17.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashanth Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.